Pharma Mar S.A. (PHM) - Total Assets
Based on the latest financial reports, Pharma Mar S.A. (PHM) holds total assets worth €395.08 Million EUR (≈ $461.89 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Pharma Mar S.A. shareholders equity for net asset value and shareholders' equity analysis.
Pharma Mar S.A. - Total Assets Trend (2002–2025)
This chart illustrates how Pharma Mar S.A.'s total assets have evolved over time, based on quarterly financial data.
Pharma Mar S.A. - Asset Composition Analysis
Current Asset Composition (December 2025)
Pharma Mar S.A.'s total assets of €395.08 Million consist of 71.7% current assets and 28.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.5% |
| Accounts Receivable | €60.59 Million | 15.3% |
| Inventory | €54.10 Million | 13.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.55 Million | 0.9% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Pharma Mar S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Pharma Mar S.A..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharma Mar S.A.'s current assets represent 71.7% of total assets in 2025, an increase from 62.6% in 2002.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2025, down from 51.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 15.3% of total assets.
Pharma Mar S.A. Competitors by Total Assets
Key competitors of Pharma Mar S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Pharma Mar S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 3.03 | 3.12 |
| Quick Ratio | 2.44 | 2.41 | 3.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €189.54 Million | €167.55 Million | €177.63 Million |
Pharma Mar S.A. - Advanced Valuation Insights
This section examines the relationship between Pharma Mar S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.25 |
| Latest Market Cap to Assets Ratio | 3.95 |
| Asset Growth Rate (YoY) | 13.0% |
| Total Assets | €395.08 Million |
| Market Capitalization | $1.56 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Pharma Mar S.A.'s assets at a significant premium (3.95x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Pharma Mar S.A.'s assets grew by 13.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pharma Mar S.A. (2002–2025)
The table below shows the annual total assets of Pharma Mar S.A. from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €395.08 Million ≈ $461.89 Million |
+13.00% |
| 2024-12-31 | €349.64 Million ≈ $408.77 Million |
+2.68% |
| 2023-12-31 | €340.52 Million ≈ $398.10 Million |
-13.41% |
| 2022-12-31 | €393.26 Million ≈ $459.76 Million |
+6.75% |
| 2021-12-31 | €368.39 Million ≈ $430.68 Million |
+11.54% |
| 2020-12-31 | €330.26 Million ≈ $386.11 Million |
+164.83% |
| 2019-12-31 | €124.70 Million ≈ $145.79 Million |
-20.91% |
| 2018-12-31 | €157.68 Million ≈ $184.34 Million |
-16.00% |
| 2017-12-31 | €187.72 Million ≈ $219.46 Million |
-15.11% |
| 2016-12-31 | €221.14 Million ≈ $258.53 Million |
+4.34% |
| 2015-12-31 | €211.94 Million ≈ $247.78 Million |
+5.24% |
| 2014-12-31 | €201.39 Million ≈ $235.44 Million |
+6.35% |
| 2013-12-31 | €189.37 Million ≈ $221.39 Million |
-5.23% |
| 2012-12-31 | €199.83 Million ≈ $233.62 Million |
-8.26% |
| 2011-12-31 | €217.82 Million ≈ $254.65 Million |
-5.64% |
| 2010-12-31 | €230.82 Million ≈ $269.86 Million |
+9.23% |
| 2009-12-31 | €211.31 Million ≈ $247.05 Million |
+1.82% |
| 2008-12-31 | €207.54 Million ≈ $242.64 Million |
-10.67% |
| 2007-12-31 | €232.33 Million ≈ $271.61 Million |
+3.53% |
| 2006-12-31 | €224.41 Million ≈ $262.35 Million |
-43.00% |
| 2005-12-31 | €393.72 Million ≈ $460.30 Million |
+16.71% |
| 2004-12-31 | €337.34 Million ≈ $394.38 Million |
+22.46% |
| 2003-12-31 | €275.47 Million ≈ $322.06 Million |
+1.49% |
| 2002-12-31 | €271.43 Million ≈ $317.33 Million |
-- |
About Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more